Anal squamous cell carcinoma: standards of care, new data and ongoing clinical trials. Issue 4 (July 2021)

• Record Type: Journal Article
• Authors: Giunta, Emilio Francesco; Bregni, Giacomo; Hendlisz, Alain; Sclafani, Francesco
• Is Part Of: Current opinion in oncology. Volume 33:Issue 4(2021)
• Publication Date: 2021-07
• Subjects: anal squamous cell carcinoma -- immunotherapy -- InterAACT; Oncology -- Periodicals; 616.994
• DOI: 10.1097/CCO.0000000000000748
• Languages: English
• ISSNs: 1040-8746

Abstract

Abstract : Purpose of review: To summarize current standards of care, discuss results of recent studies and present ongoing clinical trials for anal squamous cell carcinoma (ASCC). Recent findings: Over the last year, no practice changing studies have been reported in the setting of localised ASCC. A number of retrospective analyses, however, have provided practice-informing data, such as those confirming the negative impact of low compliance to chemoradiotherapy (CRT) on patient outcomes. In contrast, and for the first time, randomized evidence has become available to inform the management of advanced tumours. The InterAACT trial represents a key milestone in the evidence-building process for this disease, establishing carboplatin plus paclitaxel as a new standard of care for treatment-naïve advanced ASCC patients. Furthermore, more data have accumulated about the value of triplet chemotherapy in the first-line setting and of immune checkpoint inhibitors (either as single agents or in combination with other agents) in the refractory setting. Summary: Recent findings have the potential to improve the treatment quality standards and overall outcome of patients with either localised or advanced ASCC. Results from ongoing clinical trials will hopefully provide useful insights into the management of this disease and further shape current treatment paradigms.